IRadimed's 3870 Pump Ramp: A Quad-System Supercycle or a Margin Squeeze?

Product transition drives record backlog and ASP, but gross margin dip and stock drawdown test the market's patience.

IRMD · Earnings Call · 2026-07-31

The Pump Pivot

IRadimed's Q2 2026 marked the first full quarter of general release production for the next-generation 3870 MR IV pump — and the numbers show a company in a controlled stress test. Revenue came in at $20.5 million, essentially flat year-over-year, as the 3860 legacy pump wound down and the 3870 ramped to 130–135 units. But management's commentary points to an inflection: bookings more than doubled shipments, and an astounding quad pump system mix is driving pricing power. Roger Susi noted: “an astounding 70% of those were replaced with our 4-channel quad pump system, thus requiring twice the number of pumps. Additionally, the ASP of this quad systems has been north of $110,000, providing well over a 20% lift in the ASP per pump.” — Roger Susi · 2026-07-31 This is not just a refresh — it's a doubling of the revenue per installed-base site, and it's showing up in lead time expansion as orders outpace production. The company's own keyword trajectory underscores the shift: "lead time," "channel quad pump system," and "ASP per pump" all surged to the top of its quarterly list, displacing the prior emphasis on legacy unit sales. The market is voting with its feet — 71 patient monitors were sold domestically, a record, while the 3870's replacement cycle is pulling forward demand from the aged 3860 fleet. Prior calls had already flagged this pull-forward: in May, Roger detailed that "more than half of these orders we've taken so far have been for this Quad systems" “— a signal that the transition was gaining velocity ahead of the full launch.” — Roger Susi, Chief Executive Officer · 2026-05-01

The Margin Squeeze and the Learning Curve

The transition carries a visible cost. Gross margin fell to 74% from 78% a year ago, and management attributes the drag to the first sizable production ramp. The margin pressure is entirely a function of manufacturing inefficiencies: "increased labor and overhead expenses" and a steep learning curve. The company is deliberately compressing the ramp — from 0 to 130+ units in Q2, to over 300 in Q3 — and expects start-up costs to be "better than 50% reduced" in Q3. As CFO John Glenn put it on guidance: “we expect the gross margin to improve in the second half of the year as 3870 volumes build and manufacturing efficiencies take hold.” — John Glenn · 2026-07-31 This is a classic product-transition trade-off: near-term margin sacrifice for a higher-ASP, structurally larger recurring revenue base. The 70% quad-mix means the installed base's disposable and service attach rate should compound once the pumps are in the field — a point noted on the call when discussing disposables growth of 14%. Roger emphasized that the inefficiencies are transient: “It's strictly learning curve. It's experience, the efficiencies come when the folks that are making these products... become sort of second nature.” — Roger Susi · 2026-07-31

De-Risking Through Backlog and Balance Sheet

The company ended the quarter with $59.1 million in cash and generated $5.9 million in operating cash flow, funding the ramp internally. The backlog is "strong," and management is guiding Q3 revenue to $23–24.5 million, implying sequential acceleration of ~12–20%, with full-year 2026 guidance reaffirmed at $91–96 million.

our bookings of the new pump were more than double what we shipped. So the backlog is building.
Roger Susi · 2026-07-31

That backlog provides visibility into Q4, where the company expects to hit a "$100 million run rate" — a milestone that would mark a step-change from the sub-$80 million pace of 2025. Prior calls set the stage: in February, management deliberately constrained first-quarter production to "130, 135 pumps" to "get them right" before doubling. “The sales team would like us to ship over 200, but we just can't do it. We're going to stay at that level.” — Roger Susi, Chief Executive Officer · 2026-05-01 That disciplined approach is now paying off in a launch that is exceeding internal expectations on both volume and mix.

Stock Context and the Investment Case

Despite the operational progress, the stock has recently pulled back: the 90-day price tape shows a -5.9% return and a 14.1% drawdown from the July 6 peak, while the full history shows a 16.5% drawdown from the February 2026 high. The market appears to be discounting the transition risk — margin compression, execution on the ramp, and the unknown depth of the replacement cycle. But the fundamental story is one of re-acceleration: the company is transitioning from a mature product to a next-gen platform with a compelling quad-system adoption driver and a clear path back to record gross margins by Q4. ASP per pump expansion, combined with a record backlog and a fortress balance sheet, makes this a high-conviction product-cycle story. The key risk is whether the production ramp can match demand without another margin step-back. So far, the company has shown it can manage the learning curve; the next two quarters will determine whether this is a genuine supercycle or a one-quarter artifact.